Spring direct naar de hoofdnavigatie of de inhoud
‘An adequate IP strategy protects innovation and creates new chances’
Home / Experts / Marthe Lindenbergh
Marthe Lindenbergh

Marthe Lindenbergh

  • Life Sciences
  • Trainee Patent Attorney
T +31 30 785 63 74

Marthe Lindenbergh obtained a Bachelor’s and Master’s degree in Biomedical Sciences at Utrecht University. During the Master-phase, she did research internships in the UMC Utrecht and at the University of California, San Francisco. Having specialized in Infection and Immunity, she continued her studies with a PhD track at Utrecht University and the Wilhelmina Children’s Hospital, where she studied the immune-modulatory functions of immune-cell-derived extracellular vesicles. In 2019 she started as a trainee patent attorney at V.O. She obtained her PhD in November 2019.

Continue reading

Working experience

  • Trainee Patent Attorney V.O. (2019-present)
  • PhD University of Utrecht (2014-2018)

Education

  • PhD Infection and Immunity, University of Utrecht (2019)
  • MSc Infection and Immunity, University ofUtrecht (2014)
  • BSc Biomedical Sciences , University of Utrecht (2012)

Publications

  • M. Mues, L. Karra, D. Romero-Moya, A. Wandler, M. J. Hangauer, O. Ksionda, Y. Thus, M.F.S. Lindenbergh, K. Shannon, M. T. McManus, J. P. Roose. “High-complexity shRNA libraries and PI3 kinase inhibition in cancer: high-fidelity synthetic lethality predictions”. Cell Reports 2019
  • M.F.S. Lindenbergh, D.G.J. Koerhuis, E.G.F. Borg, E.M. van ’t Veld, T.A.P. Driedonks, R. Wubbolts, W. Stoorvogel, M. Boes. “Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles”. Front. Imm. 2019
  • M.F.S. Lindenbergh, W. Stoorvogel. “Antigen presentation by extracellular vesicles from professional antigen-presenting cells”.  Annu. Rev. Immunol. 2018
  • A.M. Gram, T. Oosenbrug, M.F.S. Lindenbergh, C. Büll, A. Comvalius, K.J.I. Dickson, J. Wiegant, H. Vrolijk, R.J. Lebbink, R. Wolterbeek, G.J. Adema, M. Griffioen, M.H.M. Heemskerk, D.C. Tscharke, L. M. Hutt-Fletcher, E.J.H.J. Wiertz, R.C. Hoeben, M.E. Ressing. “The Epstein-Barr virus glycoprotein gp150 forms an immune-evasive glycan shield at the surface of infected cells”. PLoS Path. 2016
  • M. van Gent, A.M. Gram, I.G.J. Boer, R.J. Geerdink, M.F.S. Lindenbergh, R.J. Lebbink, E.J. Wiertz, M.E. Ressing. “Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion”.  J. Gen. Virol. 2015.

Languages

  • Dutch
  • English

See also

Also see these experts

Saskia van Doorn

Saskia van Doorn

  • European and Dutch Patent Attorney
  • Senior Associate
+31 30 785 63 61
Sjoerd Postma

Sjoerd Postma

  • Dutch Patent Attorney
  • Associate
+31 26 368 75 28
More experts

News

Three new partners for V.O.

As of 1 April 2021, three new partners have joined V.O., namely patent attorneys Jasper Groot Koerkamp, Frits Michiels and Bart Jan Niestadt.Continue reading

Two MIP Awards for V.O.

V.O. has received two awards for patent work at the Managing IP Awards 2021, which were presented in a virtual ceremony on 30 March 2021.Continue reading

Column – “All of Europe should feel free to be a bit like Leuven.”

For those who don’t know yet: In September 2020, Leuven won the iCapital Award meaning Europe has acknowledged it as the most innovative European city. As a native of Leuven, it is a great joy that many of us are proud of the city in which they live, study or work. I even dare to […]Continue reading

More news